8-K filing — Biohaven Ltd. (BHVN)
Filed: 2026-10-15 AccNo: 0001935979-26-000080 Size: 961 KB Item 1.01: Entry into a Material Definitive Agreement Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Biohaven shares are trading lower after the company announced the FDA ordered a pause on new enrollment in BHV-7000 program and issued a partial clinical hold on September 4, pending additional nonclinical metabolite data.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement
Biohaven signs a $100 million Asian licensing agreement with Ono Pharmaceutical for its Phase 3 MoDE pan IgG degrader portfolio.
Biohaven Licenses MoDE IgG Degraders To Ono For Japan, South Korea, Taiwan And ASEAN For Up To $100M Near-Term Payments Including $80M Upfront; BHV-1300 In Phase 3 For Graves' Disease
Ono will obtain an exclusive license to develop and commercialize Biohaven's MoDE pan IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states, led by BHV-1300 and including certain next-generation
Bexorg Awarded Up to $28.3 Million from ARPA-H to Advance Human Brain Translational Pharmacology for CNS Drug Development
Bexorg, a precision neurology company, received up to $28.3 million in funding from ARPA-H to extend its BrainEx perfusion technology from 24 hours to two weeks. This advancement will enable longitudinal studies of human brain pharmacology and drug responses, potentially reducing CNS drug development attrition by providing richer human brain data for AI model training and clinical trial design.